Retina

Phase 3 Duravyu insert misses key vision end point in wet AMD but cuts injections; pivotal LUCIA readout may decide its future.

A maternal high-fat diet can negatively affect the retinal structure in mice.

Hamza Shah, OD, MS, FAAO, and Carolyn Majcher, OD, FAAO, weigh in on the recent FDA approval of the drug, which has been used off-label by compounding pharmacies for nearly 2 decades.

Catch up on the top stories in optometry during the week of August 3-7.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography–based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Physicians recommend a Mediterranean or similar diet to slow the progression of age-related macular degeneration, the leading cause of irreversible vision loss in older adults.

The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the US.

Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.

i-Lumen Scientific randomly assigned its first US patient in the sham-controlled i-SIGHT2 pivotal study of its investigational, noninvasive bioelectric AMD device at Texas Retina Associates.

Lab-grown retinal endothelial cells from iPSCs rebuild mouse retinal vessels and power blood-retina barrier chips, accelerating diabetic retinopathy research and therapy discovery.

A midyear look at 2026's biggest optometry findings, from myopia control research to safety signals on red light therapy and semaglutide.

An overview of the diagnosis and evidence-based management of one of the most common causes of visual acuity reduction following intraocular surgery.

In a preference study, Karl Csaky, MD, PhD and colleagues found that lesion growth rate reduction was the primary driver of GA treatment decisions among US retina specialists, with greater risk tolerance for foveal-threatening lesions.

The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.

A case study that highlights the importance of multimodal imaging in practice for early identification of rare inherited retinal dystrophies.

The study, conducted through the OHDSI network, analyzed records from 227,971 new users of semaglutide.

Yale School of Medicine researchers outline their findings and the methods of their researcher in an exclusive interview with Optometry Times.

The benefits of consistent physical activity have been demonstrated for a host of systemic conditions.

The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.

The study reviewed 1440 peer-reviewed journal articles indexed in the Web of Science Core Collection between 2010 and 2025.

Rethinking the optometrist’s role in healthy aging.

New Turkish study links sleeve gastrectomy weight loss to clearer cornea and lens, lower eye pressure, and widened anterior chamber in 6 months.

AMD affects approximately 28 million people in the US and is a leading cause of vision loss among older adults.

Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.

Ischemic retinal disorders may signal underlying cardiovascular risk, making diagnostic imaging workup essential.